Form D · Biotechnology
CAMBRIDGE ENDOSCOPIC DEVICES INC
Framingham, MA · CIK 0001310090
Offering snapshot reported Jan 6, 2014 · SEC filing
- Reported sold
- $2.92M Offering amount: $2.92M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 26, 2012 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$60,000 → $2,924,169
- Reported investors1 → 8
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 6, 2014 | Amendment | $2,924,169 | $2,864,169vs Aug 10, 2012 | 8 | SEC filing |
| Aug 10, 2012 | Initial | $60,000 | No comparison | 1 | SEC filing |
| Oct 8, 2010 | Amendment | $3,887,640 | $887,640vs May 13, 2010 | 15 | SEC filing |
| May 13, 2010 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Feb 3, 2010 | Initial | $734,000 | No comparison | 10 | SEC filing |
| Jul 9, 2009 | Initial | $1,500,000 | No comparison | 16 | SEC filing |
| Aug 15, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 23, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 4, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-182512
Source: Form D, filed Jan 6, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Omar Amirana | Director |
| Jeff Barnes | Director |
| Howard Donnelly | Director |
| Phil Henderson | Director, Executive |
| Glen Kashuba | Director |
| Woojin Lee | Director, Executive |
| James Lousararian | Director |
| John Schulte | Director, Executive |
| Walter Winshall | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
119 Herbert St
Framingham, MA, 01702
Framingham, MA, 01702